Metoprolol tartrate 100 mg tablets exceed the nitrosamine daily intake level
Metoprolol Tartrate Tablets USP 100 mg distributed by Westminster Pharmaceuticals are being recalled because N-nitroso-metoprolol was present above the established Acceptable Daily Intake level. 4,456 bottles affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Risk-of-harm product: a nitrosamine impurity measured above the named Acceptable Daily Intake level, with no injury reported in the source.
Plain-English summary
Metoprolol Tartrate Tablets, USP, 100 mg, 1000 tablets per bottle, prescription only, manufactured by Renata PLC of Gazipur, Bangladesh and distributed by Westminster Pharmaceuticals, LLC, is being recalled. The action covers 4,456 1000-count bottles.
The stated reason is CGMP deviations: the presence of a nitrosamine, N-nitroso-metoprolol, above the established Acceptable Daily Intake level. The FDA classified the action as Class II.
Affected batches include R56240011 expiring 2/28/26 and R56240021 and R56240031 expiring 3/31/26, together with the further batches listed in the recall notice. Distribution was nationwide in the USA.
Patients holding affected batches should speak to their pharmacist or prescriber before stopping treatment, and pharmacies should follow the instructions issued by the distributor.
The recalled product
- Product
- Metoprolol Tartrate Tablets, USP, 100 mg, 1000 Tablets, Rx Only, Manufactured by: Renata PLC (General Plant -2), Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, 1700 Bangladesh, Distributed by: Westminster Pharmaceuticals, LLC, Nashville, TN 37217, NDC 69367-355-10
- Manufacturer
- Westminster Pharmaceuticals LLC
- Category
- Drug — Oral tablet
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Batch # R56240011
- Exp Date: 2/28/26
- Batch # R56240021
- R56240031
- Exp Date: 3/31/26
- Batch # R56240041
- R56240051
- R56240061
- Exp Date: 4/30/26
- Batch # R56240071
- Exp Date: 7/31/26
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Westminster Pharmaceuticals LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Westminster Pharmaceuticals LLC
See all →- HighMetoprolol tartrate tablets recalled for nitrosamine above acceptable daily intake level
FDA (Drugs) · 2025-08-20
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
FDA (Drugs) · 2018-12-19
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
FDA (Drugs) · 2018-12-19
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- CriticalFDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
FDA (Drugs) · 2018-08-29
Same hazard · nitrosamine
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over a nitrosamine impurity
FDA (Drugs) · 2026-02-11
- HighClomipramine 25 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12